Abstract: An apparatus is disclosed, comprising means for storing reference data indicative of characteristics for each of two or more amplifiers for amplifying signals in two or more respective bands, the reference data including voltage characteristics required by the particular amplifier to achieve a particular output power for a range of output power values for its respective frequency band. The apparatus may comprise means for receiving at least a first required output power for a first amplifier and a second required output power for a second amplifier, and determining, based on the reference data, the voltage characteristics required for the first amplifier to achieve the first required output power and the voltage characteristics required for the second amplifier to achieve the second required output power.

Abstract: A field-effect transistor for terahertz wave detection using a gate as an antenna includes a silicon substrate including a source and a drain formed outside a channel region surrounding the source, and a gate formed to be spaced apart from the silicon substrate and correspond to the channel region, on a dielectric layer formed on a surface of the silicon substrate, in which the drain has a width determined based on a first performance parameter associated with a terahertz wave reception rate of the field-effect transistor and the channel region has a width determined based on a second performance parameter associated with detection of a terahertz wave to be received by the field-effect transistor.

Abstract: An apparatus is disclosed, comprising means for storing reference data indicative of characteristics for each of two or more amplifiers for amplifying signals in two or more respective bands, the reference data including voltage characteristics required by the particular amplifier to achieve a particular output power for a range of output power values for its respective frequency band. The apparatus may comprise means for receiving at least a first required output power for a first amplifier and a second required output power for a second amplifier, and determining, based on the reference data, the voltage characteristics required for the first amplifier to achieve the first required output power and the voltage characteristics required for the second amplifier to achieve the second required output power.

Abstract: The disclosed apparatus includes a condensing chamber (CC) that maintains a volume of a condensate obtained from vapor emitting from a vessel, for example a reactor pressure vessel (RPV). The condensing chamber is connected to a reference leg (RL), a variable leg (VL) and a vapor or steam leg (SL). RL connection provides a flow path for the CRD drive water system backfill to flow into the CC and overflow into the VL. The excess backfill and/or condensate will be returned to the vessel, typically at a point below the liquid level within the vessel. Non-condensable gases will thereby be returned from the CC to the RPV in a substantially continuous manner, thereby tending to prevent the introduction of non-condensable gas enriched liquid from the CC into the RL and improving the tolerance and reliability of the level measurements and/or reducing thermal stresses on the various CC connections.

Abstract: The disclosed apparatus includes a condensing chamber (CC) that maintains a volume of a condensate obtained from vapor emitting from a vessel, for example a reactor pressure vessel (RPV). The condensing chamber is connected to a reference leg (RL), a variable leg (VL) and a vapor or steam leg (SL). RL connection provides a flow path for the CRD drive water system backfill to flow into the CC and overflow into the VL. The excess backfill and/or condensate will be returned to the vessel, typically at a point below the liquid level within the vessel. Non-condensable gases will thereby be returned from the CC to the RPV in a substantially continuous manner, thereby tending to prevent the introduction of non-condensable gas enriched liquid from the CC into the RL and improving the tolerance and reliability of the level measurements and/or reducing thermal stresses on the various CC connections.

Abstract: Disclosed and claimed herein are novel biocatalysts for converting racemic mixtures of amino acids to an enantiomerically pure (S) form of the amino acid, methods for their use, and the enantiomerically enriched products of such biocatalytic processes.

Abstract: An enzymatic ammonolysis process is provided for the preparation of intermediates used in preparing dipeptidyl peptidase IV inhibitors wherein the enzyme Candida antarctica lipase-B is used to catalyze the ammonolysis process.

Abstract: This invention relates to an novel Gluconobacter oxydans 2-ketoreductase useful for the synthesis of chiral alcohols. Also related are isolated nucleic acids encoding G. oxydans 2-ketoreductase enzymes, and enzyme fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated G. oxydans 2-ketoreductase polypeptides, and fragments and variants thereof, and antibodies that specifically bind to G. oxydans 2-ketoreductase polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated G. oxydans 2-ketoreductase nucleic acids, polypeptides, and antibodies, and methods of using G. oxydans 2-ketoreductase in various reactions for industrial or pharmaceutical applications.

Abstract: The invention relates to a process for the enzymatic, stereoselective reduction of ketone compounds to provide chiral alcohols, for example the compound of formula Ib:

Abstract: This invention relates to isolated or recombinant N—CBZ-deprotecting enzyme polypeptides that catalyze the removal of CBZ from CBZ-protected amino acids and alcohols, and variants, modifications, and fragments thereof. Also related are isolated nucleic acids encoding N—CBZ-deprotecting enzyme polypeptides, and variants, modifications, and fragments thereof, as well as vectors and host cells comprising these nucleic acids. The invention also relates to methods of obtaining isolated nucleic acids, polypeptides, and antibodies, and methods of using polypeptides in various reactions for industrial or pharmaceutical applications.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: This invention relates to isolated or recombinant N-CBZ-deprotecting enzyme polypeptides that catalyze the removal of CBZ from CBZ-protected amino acids and alcohols, and variants, modifications, and fragments thereof. Also related are isolated nucleic acids encoding N-CBZ-deprotecting enzyme polypeptides, and variants, modifications, and fragments thereof, as well as vectors and host cells comprising these nucleic acids. The invention also relates to methods of obtaining isolated nucleic acids, polypeptides, and antibodies, and methods of using polypeptides in various reactions for industrial or pharmaceutical applications.

Abstract: This invention relates to a recombinant Pichia pastoris formate dehydrogenase (FDH) enzyme that catalyzes the oxidation of formate to carbon dioxide and the simultaneous reduction of nicotinamide adenine dinucleotide (NAD+) to its reduced form (NADH). Also related are isolated nucleic acids encoding P. pastoris FDH polypeptides, and fragments and variants thereof, as well as vectors and host cells comprising these nucleic acids. Further related are isolated, recombinant P. pastoris FDH polypeptides, and fragments and variants thereof, and antibodies that specifically bind to P. pastoris FDH polypeptides, fragments, or variants. The invention also relates to methods of obtaining isolated P. pastoris FDH nucleic acids, polypeptides, and antibodies, and methods of using P. pastoris FDH in various reactions for industrial or pharmaceutical applications.

Abstract: An arrangement is provided for mitigating pressure loss in a steam tunnel of a boiling water reactor. To reduce pressure loss in the steam tunnel, a diverter element is operatively connected to at least one of a plurality of pipe supports in a first direction opposed to a flow of steam in the steam tunnel so as to divide the steam flow over the at least one of the plurality of pipe supports. Further, a combiner element is operatively connected to at least one of the plurality of pipe supports in a second direction in a same direction as the flow of steam in the steam tunnel so as to combine the divided steam flow over the at least one of the plurality of pipe supports into a continuous steam flow. This division and recombination of steam flow may reduce form losses caused by the at least one of the plurality of pipe supports in the steam tunnel, which may in turn mitigate pressure loss in the steam tunnel of the boiling water reactor.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: An enzymatic ammonolysis process is provided for the preparation of intermediates used in preparing dipeptidyl peptidase IV inhibitors wherein the enzyme Candida antarctica lipase-B is used to catalyze the ammonolysis process.

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.